Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2728-2732

  Lu, Karen H ^a   Garber, Judy E ^a   Cramer, Daniel W ^a   Welch, William R ^a   Niloff, Jonathan ^a   Schrag, Deborah ^a   Berkowitz, Ross S ^a   Muto, Michael G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; FEMALE; HUMAN; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033942547     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2728     Document Type: Article

References (15)

1. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1 mutation carriers. Lancet 343:692-695, 1994
2. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
3. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689, 1998
4. Muto MG, Cramer DW, Brown DL, et al: Screening for ovarian cancer: The preliminary experience of a familial ovarian cancer center. Gynecol Oncol 51:12-20, 1993
5. Parmigiani G, Berry DA, Aguilar O: Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158, 1998
6. Salazar H, Godwin AK, Daly MB, et al: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88:1810-1820, 1996
7. Johannsson OT, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998
8. Chen KT, Schooley JL, Flam MS: Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66:93S-94S, 1985 (suppl)
9. Schorge JO, Muto MG, Welch WR, et al: Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90:841-845, 1998
10. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening. Am J Obstet Gynecol 180:917-928, 1999
11. Lu KH, Cramer DW, Muto MG, et al: A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93:34-37, 1999
12. Gotlieb WH, Friedman E, Bar-Sade RB, et al: Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 90:995-1000, 1998
13. Piver MS, Jishi MF, Tsukada Y, et al: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71:2751-2755, 1993
14. Tobacman JK, Greene MH, Tucker MA, et al: Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer prone families. Lancet 2:795-797, 1982
15. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999